Contact us
English
Menu
Contact us
Patients & Families

At Feldan Therapeutics, we are dedicated to advancing therapies for diseases that continue to present challenges in patient care.

This page provides patients and families with general information about the medical conditions for which we are advancing new therapeutics, the unmet needs they are intended to address and the science behind our approach. The content is intended to be informative and supportive and does not replace personalized medical advice. 

Our therapies are investigational, which means they are still being studied and have not yet been approved by regulatory agencies such as the Food and Drug Administration (FDA) or Health Canada. Their safety and efficacy have not been established, and they may have risks and side effects that are not yet fully understood. Any data presented are preliminary and subject to change until study completion and regulatory review. 

Basal Cell Carcinoma

Basal Cell Carcinoma (BCC)

BCC is the most common form of skin cancer and the most common type of all cancers, typically developing on sun-exposed areas of the skin. 

Learn More
Mucus-Driven DIseases

Mucus-Driven Diseases

Mucus-driven diseases, including some chronic lung conditions, are characterized by thick, excessive mucus that can make breathing difficult and raise the risk of infections. 

Learn More

Basal Cell Carcinoma

FLD-103 for Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common form of skin cancer, typically developing on sun-exposed areas of the skin. One subtype of BCC is nodular BCC (nBCC), which usually shows up as a small, slow growing bump on the skin.

FLD-103 is currently being evaluated in a Phase 1 clinical trial as a potential non-surgical treatment approach for nBCC through local injection directly into the tumor.
Learn more
Mucus-Driven Diseases

FLD-201 for Mucus-Driven Diseases
Mucus-driven diseases, including some chronic lung conditions, are characterized by thick, excessive mucus that can make breathing difficult and raise the risk of infections.

FLD-201 is an investigational inhalation therapy being investigated for effects on pathways associated with mucus accumulation in chronic lung diseases. FLD-201 is currently in preclinical development.

Learn more

How Does a Medicine Reach Patients?

A clinical trial is a critical step in the development of new medicines. Clinical trials span multiple phases and are designed to evaluate the safety and effectiveness of an investigational treatment in patients, under the supervision of physicians and in accordance with strict ethical standards. Participation in a clinical trial is always voluntary and occurs only after patients receive and agree to the potential risks and benefits of the study.

Discovery & Preclinical Research

Scientists start by identifying a promising molecule.

Lab tests and preclinical studies¹ help understand how it works and if it's safe to move forward.

Phase 1

Clinical Trial: Phase 1

To assess safety & tolerability

Small group of healthy volunteers or patients

Clinical Trial Phase 2

Clinical Trial: Phase 2

To evaluate effectiveness & confirm safety

Larger group of patients

Clinical Trial Phase 3

Clinical Trial: Phase 3

To confirm effectiveness & monitor safety

Even larger group of patients

Review & Approval

Throughout all phases, regulatory agencies such as the FDA and Health Canada review study data to help evaluate patient safety protections during development.

At the end of Phase 3, they decide whether to approve the drug or treatment for public use.

Ongoing Monitoring

Even after approval, regulatory agencies continue to monitor safety and effectiveness.

Patient safety always comes first.

 ¹Preclinical studies: a research stage that takes place before human clinical trials and is designed to help researcher better understand a therapy's safety. 

*This page provides patients and families with general information about the medical conditions for which we are advancing new therapeutics, the unmet needs they are intended to address and the science behind our approach. The content is intended to be informative and supportive and does not replace personalized medical advice. Our therapies are investigational, which means they are still being studied and have not yet been approved by regulatory agencies such as the Food and Drug Administration (FDA) or Health Canada. Their safety and efficacy have not been established, and they may have risks and side effects that are not yet fully understood. Any data presented are preliminary and subject to change until study completion and regulatory review.